Do analysts recommend ELOXD or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable earnings and valuation, ELOXD or ITRM?

Eloxx Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eloxx Pharmaceuticals $6.36M 0.45 -$5.99M N/A N/A Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A

Is ELOXD or ITRM more profitable?

Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Iterum Therapeutics N/A N/A -65.54%

Do analysts rate APVO or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is APVO or ITRM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Iterum Therapeutics N/A N/A -65.54%

Do analysts rate ITRM or APM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ITRM or APM?

Aptorum Group has higher revenue and earnings than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A Aptorum Group $430K 12.67 -$1.36M N/A N/A

Is ITRM or APM more profitable?

Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Aptorum Group N/A N/A N/A

Do analysts rate ITRM or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or BGMS more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts rate BCAB or ITRM?

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, equities analysts plainly believe BioAtla is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BCAB or ITRM more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Iterum Therapeutics N/A N/A -65.54%

Iterum Therapeutics (ITRM) Competitors

$0.03 0.00 (0.00%)

As of 06/11/2026

Compare

ITRM vs. ELOX, APVO, APM, BGMS, and BCAB

Should you buy Iterum Therapeutics stock or one of its competitors? MarketBeat compares Iterum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iterum Therapeutics include Eloxx Pharmaceuticals (ELOX), Aptevo Therapeutics (APVO), Aptorum Group (APM), Cyclacel Pharmaceuticals (BGMS), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry.

How does Iterum Therapeutics compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (OTCMKTS:ELOXD) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Eloxx Pharmaceuticals has a beta of -1932.72, indicating that its stock price is 193,372% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the broader market.

Eloxx Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	0.45	-$5.99M	N/A	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Eloxx Pharmaceuticals and 0 mentions for Iterum Therapeutics. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Iterum Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Iterum Therapeutics	N/A	N/A	-65.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats Iterum Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Iterum Therapeutics compare to Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for Iterum Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Iterum Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Iterum Therapeutics	Neutral

Iterum Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Iterum Therapeutics	N/A	N/A	-65.54%

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aptevo Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market.

Iterum Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Summary

Iterum Therapeutics beats Aptevo Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Iterum Therapeutics compare to Aptorum Group?

Iterum Therapeutics (NASDAQ:ITRM) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Aptorum Group has higher revenue and earnings than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Aptorum Group	$430K	12.67	-$1.36M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

In the previous week, Aptorum Group had 5 more articles in the media than Iterum Therapeutics. MarketBeat recorded 5 mentions for Aptorum Group and 0 mentions for Iterum Therapeutics. Aptorum Group's average media sentiment score of 1.17 beat Iterum Therapeutics' score of 0.00 indicating that Aptorum Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Aptorum Group	Positive

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Aptorum Group	N/A	N/A	N/A

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aptorum Group beats Iterum Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Iterum Therapeutics compare to Cyclacel Pharmaceuticals?

Iterum Therapeutics (NASDAQ:ITRM) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its stock price is 140% less volatile than the broader market.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for Iterum Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 0.96 beat Iterum Therapeutics' score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Cyclacel Pharmaceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Iterum Therapeutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Cyclacel Pharmaceuticals	$750K	5.75	-$3M	-$4.54	N/A

Summary

Cyclacel Pharmaceuticals beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

BioAtla has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market.

Iterum Therapeutics has lower revenue, but higher earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

In the previous week, BioAtla had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for Iterum Therapeutics. BioAtla's average media sentiment score of 1.87 beat Iterum Therapeutics' score of 0.00 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Iterum Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Iterum Therapeutics	N/A	N/A	-65.54%

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, equities analysts plainly believe BioAtla is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

BioAtla beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Iterum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITRM vs. The Competition

Export

Metric	Iterum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.60M	$2.99B	$6.75B	$12.02B
Dividend Yield	N/A	1.76%	2.66%	5.61%
P/E Ratio	-0.04	12.59	20.34	22.43
Price / Sales	4.10	302.43	510.75	109.73
Price / Cash	N/A	56.52	44.01	55.64
Price / Book	-0.20	3.99	10.66	6.79
Net Income	-$24.77M	$75.85M	$3.56B	$337.66M
7 Day Performance	N/A	1.07%	0.05%	2.08%
1 Month Performance	N/A	-3.27%	0.37%	3.16%
1 Year Performance	N/A	20.00%	22.73%	27.78%

Iterum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITRM Iterum Therapeutics	0.0272 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
ELOX Eloxx Pharmaceuticals	N/A	$1.25 +237.8%	N/A	N/A	$6.34M	N/A	N/A	30	Gap Up
APVO Aptevo Therapeutics	1.8514 of 5 stars	$5.04 -3.8%	N/A	-94.2%	$6.28M	N/A	N/A	50
APM Aptorum Group	1.4084 of 5 stars	$0.98 -8.8%	N/A	-18.3%	$6.20M	N/A	N/A	30	Short Interest Decrease High Trading Volume
BGMS Cyclacel Pharmaceuticals	0.8182 of 5 stars	$1.09 +1.9%	N/A	N/A	$6.02M	$1.53M	N/A	14	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ITRM) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iterum Therapeutics (ITRM) Competitors

ITRM vs. ELOX, APVO, APM, BGMS, and BCAB

How does Iterum Therapeutics compare to Eloxx Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to Aptevo Therapeutics?

Summary

How does Iterum Therapeutics compare to Aptorum Group?

Summary

How does Iterum Therapeutics compare to Cyclacel Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to BioAtla?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iterum Therapeutics (ITRM) Competitors

ITRM vs. ELOX, APVO, APM, BGMS, and BCAB

How does Iterum Therapeutics compare to Eloxx Pharmaceuticals?

Which has more volatility and risk, ELOXD or ITRM?

Which has preferable earnings and valuation, ELOXD or ITRM?

Does the media prefer ELOXD or ITRM?

Is ELOXD or ITRM more profitable?

Do analysts recommend ELOXD or ITRM?

Do institutionals & insiders believe in ELOXD or ITRM?

Summary

How does Iterum Therapeutics compare to Aptevo Therapeutics?

Do analysts rate APVO or ITRM?

Does the media prefer APVO or ITRM?

Is APVO or ITRM more profitable?

Do insiders and institutionals hold more shares of APVO or ITRM?

Which has more risk & volatility, APVO or ITRM?

Which has stronger valuation and earnings, APVO or ITRM?

Summary

How does Iterum Therapeutics compare to Aptorum Group?

Which has preferable valuation & earnings, ITRM or APM?

Do analysts rate ITRM or APM?

Which has more volatility & risk, ITRM or APM?

Does the media favor ITRM or APM?

Is ITRM or APM more profitable?

Do institutionals & insiders hold more shares of ITRM or APM?

Summary

How does Iterum Therapeutics compare to Cyclacel Pharmaceuticals?

Which has more risk and volatility, ITRM or BGMS?

Do insiders & institutionals hold more shares of ITRM or BGMS?

Does the media favor ITRM or BGMS?

Do analysts rate ITRM or BGMS?

Is ITRM or BGMS more profitable?

Which has stronger earnings and valuation, ITRM or BGMS?

Summary

How does Iterum Therapeutics compare to BioAtla?

Which has more volatility & risk, BCAB or ITRM?

Which has stronger earnings & valuation, BCAB or ITRM?

Does the media prefer BCAB or ITRM?

Is BCAB or ITRM more profitable?

Do insiders & institutionals hold more shares of BCAB or ITRM?

Do analysts rate BCAB or ITRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools